Department of Otolaryngology-Head and Neck Surgery, National Defense Medical College of Japan, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan.
Anticancer Res. 2013 Aug;33(8):3285-9.
This retrospective study evaluated the efficacy and safety of S-1 chemotherapy for unresectable or distant metastatic head and neck cancer. S-1 is an oral anticancer agent containing a combination of 2 modulators and tegafur, which is a pro-drug of 5-fluorouracil.
S-1 was orally administered to 27 patients with unresectable and/or distant metastatic head and neck cancer at a dose based on the patient's body surface area in an outpatient setting. S-1 was administered for either 14 or 28 consecutive days followed by a 7- or 14-day rest period, respectively. We investigated the response rate, the cumulative survival rate and the time-to-progression for these patients with adverse events.
The response rate was 11.1% (three out of the 27 cases: one case of a complete response and two cases of a partial response). The cumulative survival rate of patients with squamous cell carcinoma (n=18) was 7/18 (38.9%) and 4/18 (22.2%) at 12 and 24 months, respectively, with a median survival time of eight months. Most adverse events were mild (up to grade 2).
S-1 therapy is a useful, effective anticancer treatment for unresectable or distant metastatic head and neck cancer, with relatively mild side-effects, and can be administered while maintaining the quality of life of the patient.
本回顾性研究评估了 S-1 化疗治疗不可切除或远处转移性头颈部癌症的疗效和安全性。S-1 是一种含有 2 种调节剂和替加氟的口服抗癌药物，替加氟是氟尿嘧啶的前体药物。
27 例不可切除和/或远处转移性头颈部癌症患者在门诊环境下，根据患者的体表面积，口服 S-1 治疗。S-1 连续给药 14 或 28 天，随后分别休息 7 或 14 天。我们调查了这些患者的不良反应、客观缓解率、累积生存率和无进展时间。
客观缓解率为 11.1%（27 例中有 3 例：1 例完全缓解，2 例部分缓解）。鳞状细胞癌（n=18）患者的累积生存率分别为 7/18（38.9%）和 4/18（22.2%），中位生存时间为 8 个月。大多数不良反应为轻度（最高至 2 级）。
S-1 治疗是一种用于不可切除或远处转移性头颈部癌症的有效抗癌治疗方法，具有相对较轻的副作用，并且可以在维持患者生活质量的同时进行。
